Section
A cluster randomized trial found that enhanced implementation support for group physical therapy in knee osteoarthritis did not significantly improve patient enrollment compared to foundational support, highlighting challenges in fostering
A pilot study demonstrates that a self-guided digital psychological intervention significantly reduces psychological distress and improves quality of life in patients with inflammatory rheumatic diseases, offering a scalable mental health s
A pilot randomized clinical trial demonstrates that a self-guided digital psychological intervention effectively reduces psychological distress and improves quality of life among patients with inflammatory rheumatic diseases.
A phase 1 trial demonstrates that the allogeneic CD19-targeting T cell therapy YTS109 is safe and induces clinical remission, immune resetting, and renal tissue restoration in patients with refractory systemic lupus erythematosus complicate
This cohort study reveals that low-grade MRI-detected inflammation in hand, wrist, and forefoot joints is common in healthy individuals and at-risk groups, underscoring challenges in distinguishing rheumatoid arthritis-specific inflammation
CPL’116, a novel dual JAK and ROCK inhibitor, demonstrates dose-dependent efficacy and a favorable safety profile in rheumatoid arthritis patients inadequately responsive to methotrexate, without the typical lipid or creatine kinase a
PANLAR’s 2025 evidence-based recommendations for non-systemic polyarticular JIA emphasize early treat-to-target care using methotrexate, targeted escalation to biologics when needed, region-sensitive alternatives (leflunomide, triple nbDMAR
Higher baseline serum alpha-linolenic acid levels predict reduced multiple sclerosis activity, relapses, and disability progression up to 11 years post clinical onset in a large prospective study.
A multicenter Danish study reveals a strong independent association between somatic JAK2V617F mutation—especially its variant allele frequency—and risk of ascending aortic aneurysms, suggesting targeted screening strategies.
A Swedish cohort study reveals increased use of hypnotics, anxiolytics, and antidepressants prior to autoimmune Addison’s diagnosis, highlighting mental health symptoms as early signs and the common occurrence of insomnia in AAD patients.
A recent RCT suggests intermittent fasting may improve physical function and disease activity in overweight and obese postmenopausal women with RA, but shows no significant effect on inflammation or oxidative stress markers.
An AI-based model for assessing ankylosing spondylitis severity using spinal X-rays and mSASSS demonstrates high accuracy, offering clinicians a rapid, reliable tool and reducing human resource demands.
A French multicenter study identifies type II cryoglobulinemic vasculitis in primary Sjögren disease as a strong predictor of lymphoma and mortality, necessitating enhanced clinical vigilance.
Managing disease-modifying therapies (DMTs) during pregnancy in women with multiple sclerosis significantly affects relapse risk, with anti-CD20 strategies demonstrating superior protection compared to other approaches.
A large Taiwanese cohort study links higher PM2.5 exposure to a more than threefold increased risk of developing systemic lupus erythematosus, underscoring the need for air quality policy interventions.
A German phase 2/3 trial found oral doxycycline-hydroxychloroquine as effective and safe as standard intravenous ceftriaxone followed by oral trimethoprim-sulfamethoxazole for Whipple’s disease, potentially transforming outpatient managemen
A 4-year phase 3 extension study shows that anifrolumab improves patient-reported outcomes and quality of life in systemic lupus erythematosus, with a favorable safety profile.
A phase 3 trial indicates that fMRI-detected CNS pain activation may predict which rheumatoid arthritis patients respond best to TNF inhibitor therapy.
Sarilumab demonstrates significant improvement in disease control and quality of life for patients with relapsing polymyalgia rheumatica, enabling glucocorticoid sparing and sustained remission.
Fenebrutinib, a selective BTK inhibitor, demonstrated significant reduction in new brain lesions and low relapse rates in relapsing multiple sclerosis, with a favorable safety profile in the FENopta phase 2 trial.
